Carpal tunnel syndrome in mucopolysaccharidosis I: a registry-based cohort study.

David H ViskochilJoseph MuenzerNathalie GuffonChristophe GarinM Veronica Munoz-RojasKristin A MoyDouglas T Hutchinson

Published in: Developmental medicine and child neurology (2017)

There are significant delays in diagnosing carpal tunnel syndrome (CTS) in patients with mucopolysaccharidosis I (MPS I). Enzyme replacement therapy or hematopoietic stem cell transplant do not prevent the development of CTS. Testing for CTS in patients with MPS I is recommended to prevent irreparable damage. CTS in pediatric patients should alert physicians to potential diagnosis of MPS I.

Keyphrases

replacement therapy
hematopoietic stem cell
smoking cessation
primary care
oxidative stress
human health